X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Strides Arcolab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs STRIDES SHASUN LTD - Comparison Results

STRIDES SHASUN LTD 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA STRIDES SHASUN LTD AJANTA PHARMA/
STRIDES SHASUN LTD
 
P/E (TTM) x 21.9 39.8 55.1% View Chart
P/BV x 5.2 1.0 521.4% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 AJANTA PHARMA   STRIDES SHASUN LTD
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
STRIDES SHASUN LTD
Mar-17
AJANTA PHARMA/
STRIDES SHASUN LTD
5-Yr Chart
Click to enlarge
High Rs1,8181,275 142.6%   
Low Rs1,106918 120.5%   
Sales per share (Unadj.) Rs239.5389.6 61.5%  
Earnings per share (Unadj.) Rs52.828.0 188.8%  
Cash flow per share (Unadj.) Rs59.548.9 121.7%  
Dividends per share (Unadj.) Rs04.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs230.0303.1 75.9%  
Shares outstanding (eoy) m88.7789.42 99.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.12.8 216.9%   
Avg P/E ratio x27.739.2 70.6%  
P/CF ratio (eoy) x24.622.4 109.6%  
Price / Book Value ratio x6.43.6 175.8%  
Dividend payout %016.1 0.0%   
Avg Mkt Cap Rs m129,78298,036 132.4%   
No. of employees `0006.85.8 117.2%   
Total wages/salary Rs m3,7655,881 64.0%   
Avg. sales/employee Rs Th3,128.46,005.9 52.1%   
Avg. wages/employee Rs Th554.01,014.0 54.6%   
Avg. net profit/employee Rs Th689.7431.2 159.9%   
INCOME DATA
Net Sales Rs m21,25834,834 61.0%  
Other income Rs m2421,686 14.3%   
Total revenues Rs m21,49936,520 58.9%   
Gross profit Rs m6,5846,428 102.4%  
Depreciation Rs m5961,872 31.8%   
Interest Rs m42,269 0.2%   
Profit before tax Rs m6,2263,973 156.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m04 0.0%   
Extraordinary Inc (Exp) Rs m0-1,006 0.0%   
Tax Rs m1,539470 327.5%   
Profit after tax Rs m4,6862,501 187.4%  
Gross profit margin %31.018.5 167.8%  
Effective tax rate %24.711.8 209.0%   
Net profit margin %22.07.2 307.1%  
BALANCE SHEET DATA
Current assets Rs m12,23638,165 32.1%   
Current liabilities Rs m3,46130,402 11.4%   
Net working cap to sales %41.322.3 185.2%  
Current ratio x3.51.3 281.7%  
Inventory Days Days6077 77.9%  
Debtors Days Days84104 80.9%  
Net fixed assets Rs m11,14037,639 29.6%   
Share capital Rs m177894 19.8%   
"Free" reserves Rs m20,23726,210 77.2%   
Net worth Rs m20,41427,105 75.3%   
Long term debt Rs m1016,377 0.1%   
Total assets Rs m24,48681,168 30.2%  
Interest coverage x1,519.42.8 55,236.2%   
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x0.90.4 202.3%   
Return on assets %19.25.9 325.9%  
Return on equity %23.09.2 248.8%  
Return on capital %30.512.1 253.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,66713,465 86.6%   
Fx outflow Rs m1,6164,076 39.6%   
Net fx Rs m10,0529,389 107.1%   
CASH FLOW
From Operations Rs m2,8542,881 99.1%  
From Investments Rs m-2,604-7,051 36.9%  
From Financial Activity Rs m-23,382 -0.1%  
Net Cashflow Rs m248-788 -31.5%  

Share Holding

Indian Promoters % 73.8 27.7 266.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 37.8 4.1%  
FIIs % 7.6 8.6 88.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 25.9 65.6%  
Shareholders   20,968 56,241 37.3%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   J.B.CHEMICALS  SUVEN LIFE  CIPLA  CADILA HEALTHCARE  VENUS REMEDIES  

Compare AJANTA PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 284 Points Up; FMCG & Metal Stocks Top Gainers(Closing)

Indian share markets settled higher today taking cues from their Asian peers. At the closing bell, BSE Sensex ended up by 284 points.

Related Views on News

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 11.6% (Quarterly Result Update)

Aug 1, 2018 | Updated on Aug 1, 2018

For the quarter ended June 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 11.6% YoY). Sales on the other hand came in at Rs 5 bn (up 8.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Banks are Raising FD Rates and That's Good News(Vivek Kaul's Diary)

Aug 7, 2018

Lending to the retail segment remains strong, whereas lending to the service sector has picked up dramatically.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Aug 17, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA - CIPLA COMPARISON

COMPARE AJANTA PHARMA WITH

MARKET STATS